OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
OKYO Pharma Limited (OKYO.L) Patent for treating Ocular Pain and Inflammation
OKYO PHARMA LIMITED (OKYO.L) Filing patent application for the use of Chemerin
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
OKYO PHARMA LIMITED (OKYO.L) Grant of options – Director dealings
OKYO Pharma Limited (LSE: OKYO) (“OKYO” or the “Company”), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases
OKYO PHARMA LIMITED (OKYO.L) Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
OKYO , the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce
OKYO PHARMA LIMITED (OKYO.L) CLNs to raise £1.4m, intends to list: NASDAQ
Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ
